Skip to content

Prognostic Value of Peripheral Blood Neuromodulator Among Children With Amblyopia

Prognostic Value of Peripheral Blood Neuromodulator Among Children With Amblyopia

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300068680
Enrollment
Unknown
Registered
2023-02-27
Start date
2023-03-01
Completion date
Unknown
Last updated
2023-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

amblyopia

Interventions

Strabismic group:standard amblyopia treatment
Anisometropic group:standard amblyopia treatment
Isoametropic group:standard amblyopia treatment
Visual deprivation group:standard amblyopia treatment
Mixed group:standard amblyopia treatment

Sponsors

Zhongshan Ophthalmic Center, Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
3 Years to 12 Years

Inclusion criteria

Inclusion criteria: 1) Diagnosed with amblyopia 2) 3-12 years of age 3) Able to tolerate amblyopia treatment 4) Agree to be involved in this study and agree to have a follow up visit every 3 months.

Exclusion criteria

Exclusion criteria: 1) Have previous treatment history before 2) Have pathological ocular anomalies known to cause reduced visual acuity 3) Have previous psychiatric, visual or neurological disorders 4) Have eccentric fixation and/or abnormal retinal correspondence 5) Have attention disorder and learning disability that cannot comprehend psychophysical test instructions given and/or consent for themselves

Design outcomes

Primary

MeasureTime frame
visual acuity;contrast sensitivity;stereoacuity;peripheral blood neuromodulator;

Countries

China

Contacts

Public ContactJinrong Li

Zhongshan Ophthalmic Center, Sun Yat-sen University

lijingr3@mail.sysu.edu.cn86-020-87330351

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026